The use of factor VIIa in haemorrhagic shock and intracerebral bleeding

Injury

Volumn 37, Issue 12, 2006, Pages 1172-1177

  Dutton, Richard P ^a,b   Stein, Deborah M ^a,b  

^a R ADAMS COWLEY SHOCK TRAUMA CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Acute haemorrhagic shock; Coagulopathy; Factor VIIa; Intracerebral bleeding; Resuscitation; Trauma; Traumatic Brain Injury

Indexed keywords

BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; DRUG INDICATION; HEART INFARCTION; HEMORRHAGIC SHOCK; HEMOSTASIS; HUMAN; LUNG EMBOLISM; OFF LABEL DRUG USE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STROKE; THROMBOEMBOLISM;

BLOOD COAGULATION DISORDERS; BLOOD LOSS, SURGICAL; COAGULANTS; CRANIOCEREBRAL TRAUMA; FACTOR VIIA; HUMANS; SHOCK, HEMORRHAGIC; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 33751081070     PISSN: 00201383     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.injury.2006.09.001     Document Type: Article

References (24)

1. Boffard K.D., Riou B., Warren B., et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 59 (2005) 8-18
2. Clark A.D., Gordon W.C., Walker I.D., and Tait R.C. "Last-ditch" use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 86 (2004) 120-124
3. Deveras R.A.E., and Kessler C.M. Reversal of warfarin-induced excessive anticoagulation with recombinant factor VII concentrate. Ann Intern Med 137 (2002) 884-888
4. Dutton R.P., McCunn M., Hyder M., et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma 57 (2004) 709-719
5. Dutton R.P. Initial resuscitation of the hemorrhaging patient. In: Speiss B., and Shander A. (Eds). Perioperative transfusion medicine (2006), Lippincott, Williams & Wilkins, Philadelphia 289-300
6. Ferrara A., MacArthur J.D., Wright H.K., et al. Hypothermia and acidosis worsen coagulopathy in the patient requiring massive transfusion. Am J Surg 160 (1990) 515-518
7. Friederich P.W., Henny C.P., Messelink E.J., et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomized trial. Lancet 361 (2003) 201-205
8. Geeraedts L.M.G., Kamphuisen P.W., Kaasjager H.A.H., et al. The role of recombinant factor VIIa in the treatment of life-threatening haemorrhage in blunt trauma. Inj, Int J Care Inj 36 (2005) 495-500
9. Hedner U., and Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hemat Onc 1 (2003) 112-119
10. Kenet G., Walden R., Eldad A., et al. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 354 (1999) 1879
11. Khan A.Z., Parry J.M., Crowley W.F., et al. Recombinant factor VIIa for the treatment of severe postoperative and traumatic hemorrhage. Am J Surg 189 (2005) 331-334
12. Lodge J.P.A., Jonas S., Jones R.M., et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 11 (2005) 973-979
13. Lodge J.P.A., Jonas S., Oussoultzoglou E., et al. Recombinant coagulation factor VIIa in major liver resection. Anesthesiology 102 (2005) 269-275
14. Martinowitz U., Kenet G., Segal E., et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 51 (2001) 431-439
15. Mayer S.A., Brun N.C., Begtrup K., et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352 (2005) 777-785
16. Meng Z.H., Wolberg A.S., Monroe D.M., and Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 55 (2003) 886-891
17. Monroe D.M., and Roberts H.R. Mechanism of action of high-dose factor VIIa. Points of agreement and disagreement. Arterioscler Thromb Vasc Biol 23 (2003) 8-9
18. O'Connell K.A., Wood J.J., Wise R.P., et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295 (2006) 293-298
19. O'Connell N.M., Perry D.J., Hodgson A.J., et al. Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion 43 (2003) 1711-1716
20. O'Neill P.A., Bluth M., Gloster E.S., et al. Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma 52 (2002) 400-405
21. Park P., Fewel M.E., Garton H.J., et al. Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery 53 (2003) 34-38
22. Raobaikady R., Redman J., Ball J.A., et al. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br J Anaeth 94 (2005) 586-591
23. Stein D.M., Dutton R.P., O'Connor J., et al. Determinants of futility of administration of recombinant factor VIIa in trauma. J Trauma 59 (2005) 609-615
24. Tanaka K.A., Waly A.A., Cooper W.A., and Levy J.H. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology 98 (2003) 1513-1515